SRNE - Sorrento Therapeutics, Inc.
| Previous Close | 6.800 |
| Open | 6.800 |
| Bid | 6.600 x 2900 |
| Ask | 6.650 x 4000 |
| Day's Range | 6.600 - 6.900 |
| 52 Week Range | 1.500 - 10.650 |
| Volume | 774,543 |
| Avg. Volume | 2,028,433 |
| Market Cap | 719.959M |
| Beta | 3.89 |
| PE Ratio (TTM) | 50.96 |
| EPS (TTM) | 0.130 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.42 |
- Motley Fool•13 days ago
Why Clean Energy Fuels, Sorrento Therapeutics, and iQiyi Slumped Today
From an analyst downgrade to new tariffs on China, see why these three companies fell on Thursday.
- Motley Fool•13 days ago
Why Sorrento Therapeutics, Inc. Stock Sank Today
The biotech's share price dropped on no news -- but perhaps plenty of worries.
- GlobeNewswire•15 days ago
Sorrento Acquires the Sofusa™ Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics
SAN DIEGO, July 03, 2018-- Sorrento Therapeutics, Inc. announced today that it acquired the Sofusa™ lymphatic delivery technology platform from Kimberly-Clark Corporation for targeted biopharmaceuticals, ...
- ACCESSWIRE•22 days ago
Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Monday, June 25, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red.
- GlobeNewswire•last month
Sorrento Therapeutics issues Chairman/CEO corporate update to stockholders
The notes will be convertible into shares of Sorrento common stock at a price of $7.0125 per share and will accrue interest at a rate of 5% per year. Each purchaser of the convertible notes will also receive a warrant to purchase 50% of the number of shares of Sorrento common stock into which such purchaser’s note is initially convertible. Following the closing, we expect to have approximately $50m cash on hand to execute our business plan for the remainder of 2018.
Reuters•last monthHong Kong market could open cash flood gates for U.S. biotechs
Sorrento Therapeutics Inc is among a few early-stage U.S. biotechs wary of being overlooked in a crowded New York stock market and looking at listing itself in Hong Kong as Asia's financial center rolls out the red carpet with a drastic overhaul of listing rules. Striving to catch up with New York and Shanghai as an IPO hotspot, the Hong Kong Stock Exchange announced new policies late last year that actively court biotech companies, including those that do not have a drug on the market.
- Reuters•last month
Hong Kong market could open cash flood gates for U.S. biotechs
When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent. Sorrento Therapeutics Inc is among a few early-stage U.S. biotechs wary of being overlooked in a crowded New York stock market and looking at listing itself in Hong Kong as Asia's financial center rolls out the red carpet with a drastic overhaul of listing rules.
- ACCESSWIRE•2 months ago
Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).
- Simply Wall St.•2 months ago
An Intrinsic Calculation For Sorrento Therapeutics Inc (NASDAQ:SRNE) Shows It’s 26% Undervalued
I am going to run you through how I calculated the intrinsic value of Sorrento Therapeutics Inc (NASDAQ:SRNE) using the discounted cash flow (DCF) method. If you want to learnRead More...
- GlobeNewswire•2 months ago
Consolidated Research: 2018 Summary Expectations for Sunstone Hotel Investors, Plains All American Pipeline, Sorrento Therapeutics, TD Ameritrade Holding, Meritor, and DXC Technology — Fundamental Analysis, Key Performance Indications
NEW YORK, May 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sunstone ...
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Sorrento Therapeutics and Illumina
Investor attention will now shift to President Trump's decision on the Iran nuclear accord on Tuesday at 2:00 p.m. The Dow Jones Industrial Average gained 0.39 percent to close at 24,357.32, while the S&P 500 Index rose 0.35 percent to close at 2,672.63. The Nasdaq Composite Index jumped 0.77 percent to close at 7,265.21. If Trump pulls out, which other leaders have urged him not to do, then supply will be cut, which will have the same impact as rising demand in terms of driving up prices.
- PR Newswire•3 months ago
Lifshitz & Miller LLP Announces Investigation of Cancer Genetics, Inc., Colony Northstar, Inc., Pacific Commerce Bancorp, MiMedx Group, Inc., Sorrento Therapeutics, Inc., TrueCar, Inc., and Windstream Holdings, Inc.
NEW YORK , April 24, 2018 /PRNewswire/ -- Cancer Genetics, Inc. (CGIX) Lifshitz & Miller announces investigation into possible securities law violations in connection with Cancer Genetics' announcement ...
- GlobeNewswire•3 months ago
Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on “Unite to Cure”
Dr. Ji will share his vision for the future of cellular immunotherapy using Sorrento’s anti-CD38 and anti-BCMA CAR-T cell therapy programs for treatment of Multiple Myeloma as examples. Dr. Ji will also discuss the utilization of allogeneic cell sources, including placental immune cells as well as gamma/delta T cells, for improving patient access and potentially reducing cost of cell therapies.
- CNBC•3 months ago
Cramer's lightning round: Take a long-term view on Spotify
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a newly public streaming play.
- Market Realist•4 months ago
Why the Sudden Surge in Sorrento Therapeutics’ Revenue?
What’s in Store for Sorrento Therapeutics in 2018?
- Market Realist•4 months ago
Analysts’ Ratings for Sorrento and Its Peers in March 2018
Sorrento Therapeutics (SRNE) is a clinical-stage biotechnology company. Its research programs are targeted at autoimmune, inflammatory, and neurodegenerative diseases and pain indications. Essentially, Sorrento Therapeutics is an antibody-centric company and leverages its G-MAB library to generate product candidates.
- Market Realist•4 months ago
Exploring Sorrento Therapeutics’ Research Pipeline
Sorrento Therapeutics (SRNE) aims to use its antibodies along with its proprietary targeted delivery modalities to generate therapies for cancer. Additionally, Sorrento Therapeutics has acquired late-stage biosimilar antibodies based on Erbitux, Remicade, Xolair, and Simulect. Sorrento Therapeutics expects to submit an Investigational New Drug Application (or IND) for at least one of these two programs with the FDA in 2018.
- Motley Fool•4 months ago
Why Sorrento Therapeutics Inc. Is Getting Beaten Down Today
A recent fundraising effort has investors running for the exits.
- CNBC Videos•3 months ago
Cramer's lightning round: Take a long-term view on Spotif...
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a newly public streaming play.
